Select Page

South Delhi Pharma, New Delhi, India

SYNAGIS ® (palivizumab) injection, for intramuscular use.

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.

SYNAGIS is a prescription medicine for lung infections (such as pneumonia) treatment.
INDICATIONS AND USAGE
Synagis is a respiratory syncytial virus (RSV) F protein inhibitor monoclonal
antibody indicated for the prevention of serious lower respiratory tract disease
caused by RSV in children at high risk of RSV disease.
• Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease (CHD).
• The safety and efficacy of Synagis have not been established for treatment of RSV disease.
DOSAGE FORMS & STRENGTHS
Single-dose liquid solution vials: 50 mg per 0.5 mL and 100 mg per 1 mL.
Manufactured By: MedImmune
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “SYNAGIS ® (palivizumab) injection” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Category:

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

8 + 12 =

Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease.

Palivizumab targets the fusion protein of RSV, inhibiting its entry into the cell and thereby preventing infection. Palivizumab was approved for medical use in 1998.

Reviews

There are no reviews yet.

Be the first to review “SYNAGIS ® (palivizumab) injection, for intramuscular use.”

Your email address will not be published.